• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞表面尿激酶型纤溶酶原激活物依赖性炭疽毒素对肿瘤细胞的靶向作用

Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.

作者信息

Liu S, Bugge T H, Leppla S H

机构信息

Oral Infection and Immunity Branch and Oral and Pharyngeal Cancer Branch, NIDCR, National Institutes of Health, Bethesda, Maryland 20892, USA.

出版信息

J Biol Chem. 2001 May 25;276(21):17976-84. doi: 10.1074/jbc.M011085200. Epub 2001 Mar 12.

DOI:10.1074/jbc.M011085200
PMID:11278833
Abstract

Urokinase plasminogen activator receptor (uPAR) binds pro-urokinase plasminogen activator (pro-uPA) and thereby localizes it near plasminogen, causing the generation of active uPA and plasmin on the cell surface. uPAR and uPA are overexpressed in a variety of human tumors and tumor cell lines, and expression of uPAR and uPA is highly correlated to tumor invasion and metastasis. To exploit these characteristics in the design of tumor cell-selective cytotoxins, we constructed mutated anthrax toxin-protective antigen (PrAg) proteins in which the furin cleavage site is replaced by sequences cleaved specifically by uPA. These uPA-targeted PrAg proteins were activated selectively on the surface of uPAR-expressing tumor cells in the presence of pro-uPA and plasminogen. The activated PrAg proteins caused internalization of a recombinant cytotoxin, FP59, consisting of anthrax toxin lethal factor residues 1-254 fused to the ADP-ribosylation domain of Pseudomonas exotoxin A, thereby killing the uPAR-expressing tumor cells. The activation and cytotoxicity of these uPA-targeted PrAg proteins were strictly dependent on the integrity of the tumor cell surface-associated plasminogen activation system. We also constructed a mutated PrAg protein that selectively killed tissue plasminogen activator-expressing cells. These mutated PrAg proteins may be useful as new therapeutic agents for cancer treatment.

摘要

尿激酶型纤溶酶原激活物受体(uPAR)与纤溶酶原激活物原(pro - uPA)结合,从而将其定位在纤溶酶原附近,促使在细胞表面生成活性uPA和纤溶酶。uPAR和uPA在多种人类肿瘤及肿瘤细胞系中过表达,且uPAR和uPA的表达与肿瘤侵袭和转移高度相关。为在肿瘤细胞选择性细胞毒素设计中利用这些特性,我们构建了突变的炭疽毒素保护性抗原(PrAg)蛋白,其中弗林蛋白酶切割位点被uPA特异性切割的序列所取代。在pro - uPA和纤溶酶原存在的情况下,这些靶向uPA的PrAg蛋白在表达uPAR的肿瘤细胞表面被选择性激活。激活的PrAg蛋白导致重组细胞毒素FP59内化,FP59由与铜绿假单胞菌外毒素A的ADP - 核糖基化结构域融合的炭疽毒素致死因子1 - 254残基组成,从而杀死表达uPAR的肿瘤细胞。这些靶向uPA的PrAg蛋白的激活和细胞毒性严格依赖于肿瘤细胞表面相关纤溶酶原激活系统的完整性。我们还构建了一种选择性杀死表达组织纤溶酶原激活物细胞的突变PrAg蛋白。这些突变的PrAg蛋白可能作为癌症治疗的新型治疗药物有用。

相似文献

1
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.细胞表面尿激酶型纤溶酶原激活物依赖性炭疽毒素对肿瘤细胞的靶向作用
J Biol Chem. 2001 May 25;276(21):17976-84. doi: 10.1074/jbc.M011085200. Epub 2001 Mar 12.
2
Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin.使用尿激酶激活的炭疽毒素剖析尿激酶激活途径。
Methods Mol Biol. 2009;539:175-90. doi: 10.1007/978-1-60327-003-8_10.
3
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.一种尿激酶激活的重组炭疽毒素对多种人类肿瘤细胞类型具有选择性细胞毒性。
Mol Cancer Ther. 2006 Oct;5(10):2556-62. doi: 10.1158/1535-7163.MCT-06-0315.
4
Potent antitumor activity of a urokinase-activated engineered anthrax toxin.尿激酶激活的工程化炭疽毒素具有强大的抗肿瘤活性。
Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):657-62. doi: 10.1073/pnas.0236849100. Epub 2003 Jan 13.
5
Antitumor efficacy of a urokinase activation-dependent anthrax toxin.一种尿激酶激活依赖性炭疽毒素的抗肿瘤疗效。
Mol Cancer Ther. 2006 Jan;5(1):89-96. doi: 10.1158/1535-7163.MCT-05-0163.
6
Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin.基质金属蛋白酶激活的炭疽毒素对肿瘤细胞的选择性细胞毒性
Cancer Res. 2000 Nov 1;60(21):6061-7.
7
Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).相互的尿激酶原/纤溶酶原激活动力学——由与聚(D-赖氨酸)结合的尿激酶受体形成的模板所刺激
Eur J Biochem. 1997 Apr 15;245(2):316-23. doi: 10.1111/j.1432-1033.1997.00316.x.
8
Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.纤溶酶原激活过程中尿激酶细胞受体的功能分析。受体结合对尿激酶原的酶原性质无影响。
J Biol Chem. 1996 Jun 21;271(25):14779-84. doi: 10.1074/jbc.271.25.14779.
9
Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.乳腺丝抑蛋白通过与尿激酶型纤溶酶原激活剂/尿激酶型纤溶酶原激活剂受体系统的新型相互作用来延缓细胞脱离。
Cancer Res. 2006 Apr 15;66(8):4173-81. doi: 10.1158/0008-5472.CAN-05-3514.
10
Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.在基因缺陷小鼠中产生的抗小鼠尿激酶型纤溶酶原激活物受体的鼠单克隆抗体:对体内外受体介导的尿激酶型纤溶酶原激活物活性的抑制作用
Thromb Haemost. 2007 Jun;97(6):1013-22.

引用本文的文献

1
Anthrax: Transmission, Pathogenesis, Prevention and Treatment.炭疽:传播、发病机制、预防与治疗
Toxins (Basel). 2025 Jan 24;17(2):56. doi: 10.3390/toxins17020056.
2
Anthrax lethal toxin exerts potent metabolic inhibition of the cardiovascular system.炭疽致死毒素对心血管系统具有强大的代谢抑制作用。
mBio. 2024 Dec 11;15(12):e0216024. doi: 10.1128/mbio.02160-24. Epub 2024 Nov 7.
3
Targeting canine mammary neoplastic epithelial cells with a reengineered anthrax toxin: first study.用工程化炭疽毒素靶向犬乳腺肿瘤上皮细胞:初步研究。
Vet Res Commun. 2024 Aug;48(4):2407-2428. doi: 10.1007/s11259-024-10400-5. Epub 2024 May 28.
4
Cancer Drug Delivery Systems Using Bacterial Toxin Translocation Mechanisms.利用细菌毒素转位机制的癌症药物递送系统
Bioengineering (Basel). 2023 Jul 7;10(7):813. doi: 10.3390/bioengineering10070813.
5
AB Toxins as High-Affinity Ligands for Cell Targeting in Cancer Therapy.AB 毒素作为癌症治疗中细胞靶向的高亲和力配体。
Int J Mol Sci. 2023 Jul 7;24(13):11227. doi: 10.3390/ijms241311227.
6
A potent tumor-selective ERK pathway inactivator with high therapeutic index.一种具有高治疗指数的强效肿瘤选择性ERK通路抑制剂。
PNAS Nexus. 2022 Jul 1;1(3):pgac104. doi: 10.1093/pnasnexus/pgac104. eCollection 2022 Jul.
7
Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.利用膜锚定丝氨酸蛋白酶激活的工程炭疽致死因子对转移性卵巢癌进行选择性靶向治疗。
Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2201423119. doi: 10.1073/pnas.2201423119. Epub 2022 Jul 8.
8
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
9
Protease-triggered bioresponsive drug delivery for the targeted theranostics of malignancy.蛋白酶触发的生物响应性药物递送用于恶性肿瘤的靶向治疗诊断。
Acta Pharm Sin B. 2021 Aug;11(8):2220-2242. doi: 10.1016/j.apsb.2021.01.017. Epub 2021 Jan 24.
10
Natural and Designed Toxins for Precise Therapy: Modern Approaches in Experimental Oncology.天然与设计毒素用于精准治疗:实验肿瘤学的现代方法。
Int J Mol Sci. 2021 May 7;22(9):4975. doi: 10.3390/ijms22094975.